[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-405641-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-405641-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dose-escalation-of-oropharyngeal-cancer-long-time-follow-up-and-side-effects","Dose Escalation of Oropharyngeal Cancer - Long-Time Follow-Up and Side Effects","","Dose-escalated radiotherapy in head and neck cancer has produced mixed evidence, with uncertainty about which patients benefit and whether late toxicity is truly unaffected. This study compared 215 patients with oropharyngeal cancer treated with higher-dose radiotherapy (>72 Gy, EQD2) against 215 matched patients treated with standard external-beam radiotherapy (68 Gy) from 2011–2018, focusing on survival and toxicity. Five-year overall survival was similar; however, grade ≥3 osteoradionecrosis and late dysphagia were more frequent after dose escalation, and no predictive factors were identified.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dose-escalation-of-oropharyngeal-cancer-long-time-follow-up-and-side-effects/405641/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dose-escalation-of-oropharyngeal-cancer-long-time-follow-up-and-side-effects/405641.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was compared in this study on oropharyngeal cancer treatment?","Question",{"text":63,"@type":64},"The study compared survival and side effects between two cohorts: patients treated with dose-escalated radiotherapy (>72 Gy, EQD2) and patients treated with standard-dose external-beam radiotherapy (68 Gy). Each group included 215 patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Did dose escalation improve overall survival?",{"text":68,"@type":64},"Five-year overall survival was not significantly different between the dose-escalated and standard-dose groups (p = 0.24), indicating similar survival outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which late side effects were more common after dose escalation?",{"text":72,"@type":64},"Grade ≥3 osteoradionecrosis and late dysphagia occurred more often in the dose-escalated group than in the standard-dose group, with osteoradionecrosis rates of 8.8% vs 1.9% and dysphagia rates of 18.1% vs 9.8%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},405641,1790618177,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","cancers   \nArticle  \nDose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects  \nAnna Embring 1,2, *, Eva Onjukka 2,3, Claes Mercke 1,2, Ingmar Lax 2,3, Anders Berglund 4 and Signe Friesland 1,2  \nCitation: Embring, A.; Onjukka, E.; Mercke, C.; Lax, I.; Berglund, A.; Friesland, S. Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects. Cancers 2023, 15, 2580. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers15092580](10.3390/cancers15092580)  \nAcademic Editors: Primož Strojan and Esther G.C. Troost  \nReceived: 4 February 2023  \nRevised: 13 April 2023  \nAccepted: 29 April 2023  \nPublished: 30 April 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Oncology, Karolinska University Hospital, 17176 Stockholm, Sweden  \n2 Karolinska Institute, Department of Oncology-Pathology, 17176 Stockholm, Sweden; [ingmar.lax@ki.se](ingmar.lax@ki.se) (I.L.)  \n3 Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital,  \n17176 Stockholm, Sweden  \n4 Epistat Epidemiology and Statistics Consulting, 75655 Uppsala, Sweden; [anders.berglund@epistat.se](anders.berglund@epistat.se)  \n* Correspondence: [anna.embring@ki.se](anna.embring@ki.se)  \nSimple Summary: In head and neck cancer, local recurrences are unfortunately common. A more intense local treatment, such as an increased radiation dose to the primary tumour, could potentially prevent some of these recurrencies. Previous studies have not shown an increased risk of side effects with a higher radiotherapy dose. However, the follow-up time in these studies is sometimes limited, and late side effects may then be missed. In our study with a relatively long patient follow-up, we compared survival and side effects in two groups with 215 patients in each group, where one group was treated with standard dose radiotherapy and the other group was treated with a higher dose of radiotherapy. In this study, we found that certain severe side effects are more common after higher doses of radiotherapy compared to after treatment with standard dose radiotherapy.  \nAbstract: Previous studies on dose-escalated radiotherapy in head and neck cancer have shown mixed results, and it is not established which patients would benefit from dose escalation. Further, while dose escalation does not appear to increase late toxicity, this needs to be confirmed with longer followup. In this study, we analysed treatment outcome and toxicity in 215 patients with oropharyngeal cancer treated with dose-escalated radiotherapy (>72 Gy, EQD2, 􀀋/􀀌 = 10 Gy, boost by brachytherapy or simultaneous integrated boost) and a matched cohort of 215 patients treated with standard dose external-beam radiotherapy (68 Gy) between 2011 and 2018 at our institution. The 5-year overall survival (OS) was 77.8%(72.4–83.6) and 73.7%(67.8–80.1) in the dose-escalated and standard dose group, respectively (p = 0.24) . Median follow-up was 78.1 (49.2–98.4) and 60.2 (38.9–89.4) months in the dose-escalated and standard dose groups, respectively. Grade 􀀕3 osteoradionecrosis (ORN) and late dysphagia were more common in the dose-escalated group compared to the standard dose group, with 19 (8.8%) vs. 4 (1.9%) patients developing grade 􀀕3 ORN (p = 0.001), and 39 (18.1%) vs. 21 (9.8%) patients developing grade 􀀕3 dysphagia (p = 0.01) . No predictive factors to help select patients for dose-escalated radiotherapy were found. However, the remarkably good OS in the dose-escalated cohort, despite a predominance of advanced tumour stages, encourages further attempts to identify such factors.  \nKeywords: radiotherapy; dose escalation; oropharyngeal ca","cbCaiiOr72JtP1Xp","https://ap.wps.com/l/cbCaiiOr72JtP1Xp","pdf",1016125,15,"English","# 1. Introduction\n## Local recurrence and rationale for dose escalation\n## Clinical challenge and need for longer follow-up\n# Simple Summary\n## Study design and main finding\n# Abstract\n## Study groups, endpoints, and toxicity results","[{\"question\":\"What was compared in this study on oropharyngeal cancer treatment?\",\"answer\":\"The study compared survival and side effects between two cohorts: patients treated with dose-escalated radiotherapy (\\u003e72 Gy, EQD2) and patients treated with standard-dose external-beam radiotherapy (68 Gy). Each group included 215 patients.\"},{\"question\":\"Did dose escalation improve overall survival?\",\"answer\":\"Five-year overall survival was not significantly different between the dose-escalated and standard-dose groups (p = 0.24), indicating similar survival outcomes.\"},{\"question\":\"Which late side effects were more common after dose escalation?\",\"answer\":\"Grade ≥3 osteoradionecrosis and late dysphagia occurred more often in the dose-escalated group than in the standard-dose group, with osteoradionecrosis rates of 8.8% vs 1.9% and dysphagia rates of 18.1% vs 9.8%.\"}]","Dose Escalation of Oropharyngeal Cancer - Long-Time Follow-Up and Side Effects | PDF",1790561252,38]